VPS33A

Across TCGA pan-cancer cohorts, VPS33A mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of VPS33A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where VPS33A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types VPS33A is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

CCRCC, PDAC, and LSCC are the cancer types where VPS33A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in VPS33A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	+0.157	<.001	9	view →
PDAC	Male	II,III,IV	+0.524	<.001	8	view →
LSCC	Male	II,III,IV	−0.354	<.001	8	view →
HNSC	Male	All	+0.253	<.001	8	view →
LUAD	All	II,III,IV	−0.075	.017	3	view →
OV	All	All	+0.523	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

VPS33A–CCRCC

Open the CCRCC breakdown →